Molecular diagnostics firm BillionToOne reported after the close of the market on Tuesday that its Q3 2025 revenues more than doubled year over year.

Pillar Biosciences and AstraZeneca said Monday that they are expanding their collaboration on liquid biopsy testing to include China.

JP Morgan, BTIG, and Jefferies announced separately Monday that they have initiated coverage of molecular diagnostics firm BillionToOne.

Mirxes said Wednesday that is has partnered with Nagawa Pharmaceutical to accelerate development and implementation of its early cancer screening tests across Japan.

The University of California, Los Angeles School of Dentistry and South Korean semiconductor firm Dongwoon Anatech said on Friday that they have inked a three-year agreement worth upward of $2.4 million for the development of saliva-based liquid biopsy technologies.

Personalis said this week that it has extended its strategic collaboration with Tempus AI to include colorectal cancer (CRC) among the indications covered by their existing, exclusive commercialization agreement.

GeneCentric Therapeutics, a company making precision medicine more precise through gene expression, today announced the initial closing of an $8.0 million Series C financing. The proceeds will be used to launch and commercialize GeneCentric’s GenomicsNext™, the first integrated platform for comprehensive liquid biopsy testing that simultaneously provides thousands of gene expression measurements and high-fidelity DNA variant detection from circulating tumor DNA (ctDNA) in one sample. This novel gene expression platform will accelerate the growth of GeneCentric’s pipeline of predictive response signatures for oncology therapeutics development.

Gene Solutions and Topgen Biomedical Technology said Thursday that they have entered a partnership under which Shaoxing, China-based Topgen will offer various genomic tests developed by Gene Solutions for cancer early detection and monitoring.

Singapore-based microRNA diagnostics firm MiRxes said Thursday that it has launched an initial public offering on the Hong Kong Stock Exchange, selling 46,620,000 Hong Kong offer shares and 41,958,000 international offer shares at HK$23.30 (US$2.98) per share for approximately HK$880.5 million (US$112.8 million) in net proceeds.

Dutch diagnostics firm MRC Holland said Thursday that its liquid biopsy test for Peutz-Jeghers syndrome has been certified under Europe's In Vitro Diagnostic Regulation (IVDR).